(-0.46%) 5 048.42 points
(-0.98%) 38 086 points
(-0.64%) 15 612 points
(1.16%) $83.77
(-2.60%) $1.610
(0.27%) $2 344.60
(0.44%) $27.47
(1.11%) $926.00
(-0.27%) $0.932
(-0.25%) $10.96
(-0.38%) $0.799
(-0.13%) $92.21
@ $9.74
Issued: 8 Feb 2024 @ 15:22
Return: -64.99%
Live Chart Being Loaded With Signals
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases...
Stats | |
---|---|
Today's Volume | 7 324.00 |
Average Volume | 632 346 |
Market Cap | 4.68M |
EPS | $0 ( 2024-04-11 ) |
Next earnings date | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.110 |
ATR14 | $0.0470 (1.43%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Marchio Albert N Ii | Buy | 0 | |
2023-11-21 | Roemer Alan S. | Sell | 3 833 | Common Stock |
2023-11-22 | Roemer Alan S. | Sell | 3 992 | Common Stock |
2023-08-30 | Stover Timothy | Sell | 0 | Common Stock |
2023-08-30 | Stover Timothy | Sell | 6 375 | Stock Option (right to buy) |
INSIDER POWER |
---|
28.30 |
Last 99 transactions |
Buy: 3 627 952 | Sell: 1 972 123 |
Volume Correlation
NexImmune, Inc. Common Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
NexImmune, Inc. Common Correlation - Currency/Commodity
NexImmune, Inc. Common Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-1.02M (0.00 %) |
EPS: | $-30.82 |
Q4 | 2023 |
Revenue: | $0 |
Gross Profit: | $-228 509 (0.00 %) |
EPS: | $-5.03 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-265 542 (0.00 %) |
EPS: | $-235.10 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-400 231 (0.00 %) |
EPS: | $-7.25 |
Financial Reports:
No articles found.
NexImmune, Inc. Common
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators